Pharmacotherapy of benign prostatic hypertrophy with α1-adrenoceptor antagonists

Pharmacology Reviews and Communications

Volumn 8, Issue 4, 1996, Pages 251-256

  Hieble, J Paul ^a   Ruffolo Jr , Robert R ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

1 adrenoceptors; 1A adrenoceptors; 1L adrenoceptors; Alfuzosin; Doxazosin; Phenoxybenzamine; Prazosin; Stromal smooth muscle; Tamsulosin; Terazosin; Urethral obstruction; Uroselectivity

Indexed keywords

EID: 3042943035     PISSN: 10288945     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Abrams, P. H., Schulman, C. C. and Vaage, S (1995). The efficacy and safety of 0.4 mg tamsulosin once daily in symptomatic BPH. J. Urol., 153 (Suppl), 274A.
2. Abrams, P. H., Shah, P. J. R., Stone, R. and Choa, R. G. (1982). Bladder outflow obstruction treated with phenoxybenzamime. Brit. J. Urol., 54, 527-30.
3. 1-Blockers vs. 5α-reductase inhibitors in benign prostatic hyperplasia: A Comparative Review. Drugs & Aging, 6(5), 388-96.
4. Buzelin, J. M., Geffriaud-Ricouard, C, Delauche-Cavallier, M. C., Weber, F., Proffit, O. and Roth S. (1995). A double-blind placebo-controlled trial of the efficacy and safety of sustained-release alfuzosin in symptomatic benign prostatic hyperplasia. J. Urol., 153 (Suppl.), 274A.
5. Caine, M., Perlberg, S. and Meretyk, S. (1978). A placebo-controlled double blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Brit. J. Urol., 50, 551-54.
6. Caine, M. and Perlberg, S. (1977). Dynamics of acute retention in prostatic patient and role of adrenergic receptors. Urology, 9, 399-403.
7. Caine, M. (1990). Alpha-adrenergic blockers for the treatment of benign prostatic hyperplasia. Urol. Clin. North Am., 17, 641-49.
8. Caine, M. (1983). Phenoxybenzamine in beingn prostatic hypertrophy. Urology, 22, 353-52.
9. 1-adrenoceptor subtypes in the human prostate. Br. J. Urol., 74, 585-89.
10. Chapple, C. R., Carter P. and Christmas, T. J., et al. (1994a). A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Brit. J. Urol., 74, 50-6.
11. Chow, W., Hahn, D. and Sandhu, D., et al. (1990) Multicentre controlled trial of indoramin in the symptomatic relief of benign prostatic hypertrophy. Br. J. Urol., 65, 36-8.
12. Fawzy, A., Braun, K., Lewis, G. P., Gaffney, M., Ice, K. and Dias, N. (1995). Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: A multicenter Study. J. Urol., 154, 105-109.
13. Flavahan, N. A. and Vanhoutte, P. M. (1986). α-Adrenoceptor subclassification in vascular smooth muscle. Trends in Pharmacol. Sci., 7, 347-49.
14. 1A adrenoceptor antagonist, RS 17053. Br. J. Pharmacol., 114, 24P.
15. 1-adrenoceptors in prostate of man: Implications for adrenoceptor classification. Mol. Pharmacol., 49, 209-215.
16. 1C-subtype. Mol. Pharmacol. 45, 703-708.
17. Forray, C., Chiu, G., Wetzel, J. J., Bard, J. A., Weinshank, R. L., Branchek, T. A., Hartig, P. and Gluchowski, C. (1994b). Effects of novel alpha-1C adrenergic receptor antagonists on the contraction of human prostate smooth muscle. J. Urol., 151(5), 267A.
18. Fujita, T., Ohshima, S, Asano, H., Ono, Y., Kinukawa, T., Kato, N. and Hirabayashi, S. (1992). The evaluation of the effects of bunazosin hydrochloride in the treatment of prostatic hyperplasia. Acta Urol. Jpn., 38, 613-621
19. Gilberti, C., Damonte, P., Michelotti, P. and Martorana, G. (1984). The effect of thymoxamine in benign prostatic hypertrophy: A double blind cross-over study. IRCS Med. Sci., 12, 591.
20. 1C specific compounds to treat benign prostatic hyperplasia. U.S. Patent No. 5,403,847; April 4, 1995.
21. 1-Adrenoceptor subtypes in the human prostate and internal iliac artery-autoradiographic analysis using imaging plates and BAS3000. J. Urol., 151(5), 298A.
22. Hieble, J P., Caine, M. and Zalaznik, E. (1985). In vitro characterization of the alpha-adrenoceptors in human prostate. Eur. J. Pharmacol., 107, 111-17.
23. Hieble, J. P. and Ruffolo, R. R., Jr. (1996). The use of alpha-adrenoceptor antagonists in the pharmacological management of benign prostatic hypertrophy: An overview. Pharmacological Research, in press.
24. 1-blocker, YM617, in the treatment of benign prostatic hypertrophy. J. Urol., 144, 908-912.
25. 1-adrenoceptor antagonists on prostatic pressure and blood pressure in the anesthetised dog. Urology, 44, 52-57.
26. Kirby, R. S., Coppinger, S. W. C. and Corcoran, M. O. et al. (1987). Prazosin in benign prostatic obstruction: a placebo-controlled study. Brit. J. Urol., 60, 136-42.
27. 1-Adrenoceptors: Subtype and organ-selectivity of different agents. In: D. Giardina, A. Piergentili and M Pigini, eds, Perspectives in Receptor Research, Proceedings of the Tenth Camerino-Noodwijkerout Symposium.
28. Lepor, H., Auerbach, S. and Puras-Baez, A. et al. (1992a). A randomized placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J. Urol., 148, 1467-474.
29. Lepor, H., Meretyk, S. and Knapp-Maloney, G. (1992b). The safety, efficacy and compliance of terazosin therapy for benign prostatic hyperplasia. J. Urol., 147, 1554-1557.
30. 1A-adrenoceptor in the human prostate. J. Urol., 154, 2096-99.
31. 1C antagonist. J. Urol., 153 (Suppl.), 274A.
32. 1C-) adrenoceptor subtype. Br. J. Pharmacol., 115, 781-86.
33. 1C-adrenoceptor: functional characterization in prostate. Br. J. Pharmacol., 112, 59P.
34. 1A-Adrenergic receptors in the isolated human prostate. Pharmacol. Comm., 4(3), 181-88.
35. 1-selective antagonist. Acta Histochem. Cytochem., 27(3), 219-25.
36. 1-adrenoceptors in vascular smooth muscle. Brit. J. Pharmacol., 99, 197-201.
37. 1-adrenoceptor subtypes in the human prostate: functional and binding studies. Br. J. Urol., 74, 572-578.
38. 1-adrenergic receptor subtypes in human prostate. J. Urol., 150, 546-51.
39. Reuther, K. and Aagaard, J. (1984). Acute retention of urine due to benign prostatic obstruction treated with alpha-adrenergic blockers. Urol. Int., 39, 114-159.
40. Ronchi, F., Margonato, A., Ceccardi, R., Rigatri, P. and Rossine, B. M. (1982). Symptomatic treatment of benign prostatic obstruction with nicergoline: A placebo controlled clinical study and urodynamic evaluation. Urol. Res., 10, 131-34.
41. Scott, M. A. and Abrams, P. H. (1991). Indoramin in benign prostatic hypertrophy: A placebo controlled trial. Br. J. Urol., 67, 499-501.
42. 1-adrenoceptors and native tissue. Mol. Pharmacol., 48, 250-58.
43. 1-antagonist selective for the lower urinary tract: in vivo studies. Neurourology and Urodynamics, 13, 471-73.
44. 1-adrenoceptor antagonist. Pharmacol. Commun., 6, 79-86.
45. 1c-adrenoceptor in human prostate. cloning, functional expression, and localization to specific prostatic cell types. Brit. J. Pharmacol., 115, 1475-485.
46. Wilde, M. I., Fitton, A. and McTavish, D. (1993). Alfuzosin: A review of its Pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs, 45(3), 410-29.
47. 1-adrenoceptor antagonists to prostatic α-adrenoceptors in benign prostatic hypertrophy. Life Sci., 50, 127-35.
48. 1-adrenoceptor antagonist binding in human prostate and aorta. Clin. & Exp. Pharmacol. & Physiol., 21, 405-11.
49. Yamamaguchi O., Shiraiwa Y., Kobayashi M., Yokota T. and Ohinata M. Clinical evaluation of effects of prazosin with benign prostatic obstruction: a double blind, multi-international paraprost control study. Urologia Internationalis 45 (Suppl. 1) 4-16, 1990.
50. Yamanaka, N., Yamaguchi, O., Kameoka, H., Fukaya, Y., Yokoto, T. and Shiraiwa, Y. (1991). Effect of KT-611 (naftopidil) on the contraction of human prostatic tissue and its use in benign prostatic obstruction. Acta Urol. Jpn., 37, 1759-772.